The Medicines Patent Pool is a public health organisation working to increase access to HIV, viral hepatitis C and tuberculosis treatments in low- and middle-income countries.
To date, the MPP has secured licences for twelve WHO preferred first-line and second-line HIV treatments for both adults and children over three years of age: raltegravir (RAL), lopinavir/ritonavir (LPV/r) for paediatric use, tenofovir alafenamide (TAF), dolutegravir (DTG) for both paediatric and adult care, atazanavir (ATV), tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), elvitegravir (EVG), cobicistat (COBI), abacavir (ABC) for paediatric use and darunavir (DRV). The MPP also negociated one licence for daclatasvir (DCV), a hepatitis C treatment.
The MPP has also sub-licensed to generic manufacturers, who are already beginning to produce and supply HIV medicines at a lower cost. As of January 2015, the Medicines Patent Pool had signed sub-licensing agreements with fifteen key generic manufacturers: Aurobindo Pharma Limited, Beximco, Cipla, Desano, Emcure Pharmaceuticals, Hetero Labs, Huahai Pharmaceutical, Laurus Labs, Lupin, Micro Labs, Mylan, Sandoz, Strides Arcolab and Zydus Cadila.